Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of upadacitinib in severe alopecia areata in adults and adolescents
CTR20233956Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in alopecia areata, sponsored by AbbVie Inc.. Started Mar 2024; status: active.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20233956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233956.